Scleral Lenses for Keratoconus Cost $1,800-$5,000 with Poor Insurance Coverage

Keratoconus is a progressive eye condition where the cornea thins and bulges into a cone shape, causing distorted vision that glasses cannot fully correct. For moderate to advanced cases, scleral contact lenses — large rigid lenses that vault over the entire cornea — are often the only non-surgical option to restore functional vision. These lenses cost $700-$900 per lens, and the total cost including fitting ranges from $1,800 to $5,000 per pair. Some advanced designs (PROSE devices) cost $5,000-$7,000 per eye. So what? Keratoconus affects approximately 1 in 2,000 people and is often diagnosed in teenagers and young adults — a population that is least able to absorb thousands of dollars in out-of-pocket costs. Scleral lenses must be replaced every 1-2 years, making this a recurring expense of thousands of dollars annually. For many patients, these lenses are not optional: without them, they cannot drive, work at a computer, or function normally. Yet the cost puts them out of reach for many patients, forcing them toward corneal transplant surgery (which carries its own risks and costs) or simply living with severely impaired vision. Insurance coverage for scleral lenses is inconsistent and confusing. Medical insurance typically does not cover them. Vision insurance plans like VSP and EyeMed may cover a significant portion, but only through employer-sponsored group plans — individual plans generally lack contact lens provisions. Medicare may cover scleral lenses under its prosthetic device benefit, but only with extensive documentation proving medical necessity. The process of getting insurance approval often requires months of paperwork, prior authorization, and appeals. Why does this persist? Scleral lenses are a niche product: the market is too small for economies of scale, so each lens requires custom manufacturing, precision fitting over multiple visits, and specialized expertise that few practitioners have. The fitting process alone may require 3-5 office visits. Insurance companies classify scleral lenses inconsistently — sometimes as a medical device, sometimes as a vision product, sometimes as a prosthetic — and this classification ambiguity lets them deny or minimize coverage. The structural issue is that keratoconus sits in the gap between 'medical' and 'vision' insurance. Vision insurance treats it as beyond its scope (it is a disease, not a refractive error), while medical insurance treats contact lenses as a vision product. Patients fall through this gap, paying out of pocket for a device that is as medically necessary as a hearing aid or prosthetic limb.